A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.


Updates from The Motley Fool

Latest updates on Amicus Therapeutics from Fool.com.  The Fool has written over 100 articles on Amicus Therapeutics.


Stock Performance

View Interactive FOLD Charts
Sponsored by

Key Data Points

Primary metrics and data points about Amicus Therapeutics.
Current Price: $6.00
Prev Close: $6.05
Open: $6.00
Bid: $5.99
Ask: $6.00
Day's Range: $5.88 - $6.02
52wk Range: $4.41 - $9.83
Volume: 275,919
Avg Vol 3,106,554
Market Cap: $855M
P/E (ttm): -4.26
EPS (ttm): ($1.42)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Amicus Therapeutics.
CAPS Rating 2 out of 5
 
100 Outperform
25 Underperform
CAPS All Stars
 
19 Outperform
9 Underperform

How do you think Amicus Therapeutics will perform against the market?



You pick for Amicus Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John F. Crowley, CEO

85% Approve

Based on 9 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Amicus Therapeutics.

A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers